Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.43 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.38 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.36 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.36 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1799442 | 1.00 | HRH3 (0.50) | HRH3KMT2AMEN1LMNACHRM5 | |
| SCHEMBL348065 | 1.00 | HRH3 (0.50) | HRH3KMT2AMEN1LMNACHRM5 | |
| SCHEMBL3558131 | 0.96 | HRH3 (0.47) | HRH3KMT2AMEN1LMNACHRM5 | |
| Hydrochloric Acid SCHEMBL10442200 | 0.96 | HRH3 (0.47) | HRH3KMT2AMEN1LMNACHRM5 | |
| Hydrochloric Acid SCHEMBL22322297 | 0.96 | HRH3 (0.47) | HRH3KMT2AMEN1LMNACHRM5 | |
| SCHEMBL277482 | 0.96 | LMNA (0.47) | HRH3KMT2AMEN1LMNACHRM5 | |
| Hydrochloric Acid SCHEMBL10442465 | 0.93 | HRH3 (0.45) | HRH3KMT2AMEN1LMNACHRM5 | |
| SCHEMBL3553239 | 0.92 | LMNA (0.44) | HRH3KMT2AMEN1LMNACHRM5 | |
| SCHEMBL13776923 | 0.87 | — | — | |
| SCHEMBL20363777 | 0.85 | LMNA (0.40) | HRH3KMT2AMEN1LMNACHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6599921-B2 | Antiproliferative agents against estrogen-dependent cancer cells dibenzothiopyran, dibenzopyran and phenanthrene derivatives | NANODESIGN, INC. (CA) | 2003-07-29 | — | — | US | claimed |
| EP-0333427-B1 | Heterocyclic derivatives | SMITHKLINE BEECHAM FARMA (IT) | 1995-08-23 | — | — | EP | claimed |
| EP-0372694-A2 | Azacyclic derivatives with diuretic activity | SmithKline Beecham Farmaceutici S.p.A. (IT) | 1990-06-13 | — | — | EP | claimed |
| EP-0333315-A1 | Azacyclic compounds, processes for their preparation and their pharmaceutical use | Dr. Lo. Zambeletti S.p.A. (IT) | 1989-09-20 | — | — | EP | claimed |
| US-20240180895-A1 | USE OF KAPPA OPIOID RECEPTOR AGONISTS TO TREAT CARDIOVASCULAR DISEASE | BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE | 2024-06-06 | — | — | US | disclosed |
| US-20230181569-A1 | COMPOSITIONS AND METHODS TO TREAT POLYCYSTIC KIDNEY DISEASE | UNIV LOUISIANA STATE (US) | 2023-06-15 | — | — | US | disclosed |
| EP-3650429-A1 | CATALYST FOR OLEFIN MULTIMERIZATION AND METHOD FOR PRODUCING OLEFIN MULTIMER IN PRESENCE OF SAID CATALYST | Mitsui Chemicals, Inc. (JP) | 2020-05-13 | — | — | EP | disclosed |
| EP-2597955-A1 | QUINOLINE DERIVATIVES AND MELK INHIBITORS CONTAINING THE SAME | OncoTherapy Science, Inc. (JP) | 2013-06-05 | — | — | EP | disclosed |
| WO-2012016082-A1 | QUINOLINE DERIVATIVES AND MELK INHIBITORS CONTAINING THE SAME | ONCOTHERAPY SCIENCE, INC. (JP) | 2012-02-02 | — | — | WO | disclosed |
| EP-1349852-A2 | 4-(HETERO)ARYL SUBSTITUTED INDOLINONES | Sugen, Inc. (US) | 2003-10-08 | — | — | EP | disclosed |
| WO-2002055517-A2 | 4-(HETERO)ARYL SUBSTITUTED INDOLINONES | CUI JINGRONG (US) | 2002-07-18 | — | — | WO | disclosed |
| EP-0640081-B1 | SUBSTITUTED PHENYLCARBAMATES AND PHENYLUREAS, THEIR PREPARATION AND THEIR USE AS 5-HT4 ANTAGONISTS | GLAXO GROUP LTD (GB) | 2000-01-12 | — | — | EP | disclosed |
| EP-0333427-B1 | Heterocyclic derivatives | SMITHKLINE BEECHAM FARMA (IT) | 1995-08-23 | — | — | EP | disclosed |
| US-5270327-A | Piperidine derivatives | SANKYO COMPANY, LIMITED (JP) | 1993-12-14 | — | — | US | disclosed |
| EP-0333427-A1 | Heterocyclic derivatives | Smithkline Beecham Farmaceutici S.p.A. (IT) | 1989-09-20 | — | — | EP | disclosed |
| EP-0333315-A1 | Azacyclic compounds, processes for their preparation and their pharmaceutical use | Dr. Lo. Zambeletti S.p.A. (IT) | 1989-09-20 | — | — | EP | disclosed |
| US-4826819-A | Piperidine analgesics | DR. LO ZAMBELETTI S.P.A. (IT) | 1989-05-02 | — | — | US | disclosed |
| EP-0260041-A1 | 1-Acyl-substituted piperidine derivatives | Dr. Lo. Zambeletti S.p.A. (IT) | 1988-03-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230181569-A1 | COMPOSITIONS AND METHODS TO TREAT POLYCYSTIC KIDNEY DISEASE | OPRK1, OPRL1, AVPR1A | HRH3 1638/4885KMT2A 430/4885MEN1 3533/4885 |
| US-20240180895-A1 | USE OF KAPPA OPIOID RECEPTOR AGONISTS TO TREAT CARDIOVASCULAR DISEASE | OPRK1, OPRL1, OPRM1 | HRH3 1448/4885KMT2A 1137/4885MEN1 4770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.